Renovascular hypertension associated with JAK2 V617F positive myeloproliferative neoplasms treated with angioplasty: 2 cases and literature review

J Clin Hypertens (Greenwich). 2018 Apr;20(4):798-804. doi: 10.1111/jch.13257. Epub 2018 Apr 14.

Abstract

Myeloproliferative neoplasms (MPNs) with Janus kinase 2 (JAK2) mutation are associated with a high risk for occlusive vascular diseases. We report 2 cases of renovascular hypertension associated with JAK2 V617F mutation-positive MPNs and provide a literature review. In Case 1, a 63-year-old woman had resistant hypertension, massive proteinuria, and erythrocytosis. Evaluations revealed right renal artery stenosis causing renovascular hypertension and polycythemia vera with JAK2 V617F mutation. Renin-angiotensin system inhibitors and subsequent angioplasty controlled the blood pressure and the proteinuria resolved. In Case 2, a 74-year-old woman had resistant hypertension and thrombocytosis. Evaluations confirmed left renal artery stenosis and essential thrombocythemia with JAK2 V617F. Angioplasty cured the hypertension. A literature review of 18 cases revealed the following as the most common characteristics of MPN-associated renovascular hypertension: manifests primarily in women; is associated with untreated polycythemia vera and essential thrombocythemia, concomitant leukocytosis, and JAK2 mutation positivity; and is responsive to angioplasty. This report demonstrates that JAK2 mutation-positive MPNs are a less common but important underlying cause of adult renovascular hypertension.

Keywords: essential thrombocythemia; onco-nephrology; polycythemia vera; proteinuria; renal artery stenosis.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged
  • Amino Acid Substitution
  • Angioplasty / methods*
  • Female
  • Humans
  • Hypertension, Renovascular / etiology
  • Hypertension, Renovascular / genetics
  • Hypertension, Renovascular / therapy*
  • Janus Kinase 2 / genetics*
  • Middle Aged
  • Myeloproliferative Disorders / complications
  • Myeloproliferative Disorders / diagnosis*
  • Myeloproliferative Disorders / genetics
  • Treatment Outcome

Substances

  • JAK2 protein, human
  • Janus Kinase 2